Fondaparinux: A cornerstone drug in acute coronary syndromes

Table 7 Primary efficacy outcome of Fondaparinux vs unfractionated heparin (control) in preventing death or reinfarction at 30 d and 3 or 6 mo and relative risk reduction of fondaparinux vs control through study end

Measures	Fondaparinux	Control (UFH)
Primary composite outcome: Death or reinfarction
Frequency at 30 d	9.70%	11.20%
P value	P = 0.008
Relative risk reduction	14%
Frequency at 9 d	7.40%	8.90%
P value	P = 0.003
Relative risk reduction	17%
Frequency at 3-6 mo	13.40%	14.80%
P value	P = 0.008
Relative risk reduction	12%

UFH: Unfractionated heparin.